Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Clascoterone and Exemestane Interaction: Monitor | Peptide Database

Compound Profiles Clascoterone Topical Androgen Receptor Inhibitor | Acne & Hair Loss Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Clascoterone

Topical Androgen Receptor Inhibitor | Acne & Hair Loss

Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia).

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Clascoterone with Exemestane?

Yes, but with caution. Both Clascoterone and Exemestane carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. Regular monitoring is advised.

Is Clascoterone and Exemestane safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, teratogenic. Monitor accordingly.

What are the interactions between Clascoterone and Exemestane?

Both Clascoterone and Exemestane carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. This assessment has 60% confidence and is inferred from pharmacological mechanism analysis.

How should I time Clascoterone and Exemestane?

Clascoterone has a half-life of Short topical (local action; rapidly metabolized to cortexolone) and Exemestane has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching AICAR — share findings, ask questions, and learn from real experiences AICAR is a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis. Originally studied for cardiac ischemia protection, it gained attention as an 'exercise mimetic' due to its metabolic effects. Once inside cells, AICAR is phosphorylated to ZMP, which mimics AMP and activates AMPK. This triggers metabolic pathways typically activated during exercise: increased glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.

Source: peptide-db.com ↗

Community Research

Join others researching Ketoconazole — share findings, ask questions, and learn from real experiences Ketoconazole is an FDA-approved azole antifungal that has gained widespread use as a topical adjunct in hair loss treatment. Available as a 1-2% medicated shampoo, ketoconazole disrupts DHT binding at the hair follicle and reduces scalp inflammation driven by the fungus Malassezia, both of which contribute to follicular miniaturization. It is a core component of the widely referenced "big 3" hair loss stack alongside finasteride and minoxidil. While ketoconazole was originally developed as a systemic antifungal for conditions like fungal infections and seborrheic dermatitis, its topical anti-androgenic properties at the scalp level have made it a practical and low-risk addition to hair loss regimens. When used as a shampoo, systemic absorption is negligible, keeping the side effect profile limited to occasional local irritation. Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and killing Malassezia fungi that colonize the scalp and contribute to inflammation and seborrheic dermatitis. This anti-inflammatory effect reduces the chronic follicular inflammation associated with androgenetic alopecia. Independently, ketoconazole has demonstrated topical anti-androgenic activity by disrupting the binding of dihydrotestosterone (DHT) and other androgens to receptors at the hair follicle. Some evidence also suggests it may interfere with local androgen synthesis pathways. Unlike systemic anti-androgens such as finasteride, ketoconazole shampoo exerts these effects locally at the scalp without meaningful systemic hormonal changes, making it a well-tolerated complement to oral DHT-blocking therapies.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Cabergoline is administered orally as a tablet, typically 0.5mg per tablet. It has good oral bioavailability and its absorption is not significantly affected by food, though taking it with food can reduce gastrointestinal side effects. The exceptionally long half-life of 63-69 hours allows for twice-weekly dosing in both medical and bodybuilding contexts, making it one of the most convenient prolactin management options available. Prolactin management during 19-nor cycle (preventive) 0.25mg Twice weekly Oral Prolactin management during 19-nor cycle (active symptoms) 0.5mg Hyperprolactinemia treatment (medical, initial) Once weekly (may split into two 0.25mg doses) Hyperprolactinemia treatment (medical, maintenance) 0.5-1mg

Source: peptide-db.com ↗
Side effects

Common Side Effects

No effects on TREK-2, TRAAK, TASK-1 channels observed No cardiac dysfunction or seizures in preclinical studies

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →